

Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ

Ref: FOI-072024-000998

Date: 05/08/2024

Address / Email:

Dear

Request Under Freedom of Information Act 2000

Thank you for requesting information under the Freedom of Information Act 2000.

Request

Dear The Dudley Group NHS Foundation Trust,

I have a freedom of information request regarding the treatment of certain types of cancer. Could you please answer the following questions.

Q1. Do you treat patients for Urothelial cancer (Yes or No)? If No, where do you refer patients for treatment

Q2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

- Atezolizumab (Tecentriq)
- Avelumab (Bavencio)
- Carboplatin single agent or in any other combination
- Carboplatin with Gemcitabine
- Carboplatin with Paclitaxel
- Cisplatin single agent or in any other combination
- Cisplatin with Gemcitabine
- Cisplatin with Gemcitabine + Nivolumab (Opdivo)
- Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Other active systemic anti-cancer therapy
- Palliative care only

Q3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Q4. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Chemotherapy
- Radiotherapy
- Chemotherapy AND Radiotherapy

Response

Q1. Do you treat patients for Urothelial cancer (Yes or No)? If No, where do you refer patients for treatment.

Yes

Q2. How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments:

- Atezolizumab (Tecentriq) - <5
- Avelumab (Bavencio) – 0
- Carboplatin single agent or in any other combination – <5
- Carboplatin with Gemcitabine – <5
- Carboplatin with Paclitaxel – <5
- Cisplatin single agent or in any other combination – 0
- Cisplatin with Gemcitabine - 0
- Cisplatin with Gemcitabine + Nivolumab (Opdivo) – 0
- Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda) – 0
- Nivolumab (Opdivo) – <5
- Pembrolizumab (Keytruda) – 0
- Other active systemic anti-cancer therapy – <5
- Palliative care only – **This is not recorded on Chemocare.**

The Trust does not publish numbers lower than 5 as this could lead to the identification of the person(s) involved and cause distress to families and friends. The number of patients treated for Urothelial Cancer over the requested timeframe is less than 5, therefore Section 40(2) of the Freedom of Information Act has been applied.

Q3. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

None at the moment.

Q4. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq) – 0
- Durvalumab (Imfinzi) - 0
- Nivolumab (Opdivo) - 0
- Pembrolizumab (Keytruda) - 0
- Chemotherapy - <5
- Radiotherapy – **This is not recorded on Chemocare.**
- Chemotherapy AND Radiotherapy – 0

The Trust does not publish numbers lower than 5 as this could lead to the identification of the person(s) involved and cause distress to families and friends. The number of patients treated for Urothelial Cancer over the requested timeframe is less than 5, therefore Section 40(2) of the Freedom of Information Act has been applied.

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager
Trust Headquarters
Russell's Hall Hospital
Dudley
West Midlands
DY1 2HQ
Email: dgft.dpo@nhs.net

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Tel: 0303 123 1113
www.ico.org.uk

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

Freedom of Information Team
The Dudley Group NHS Foundation Trust